The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis

Roly D. Gosling, Leonard O. Uiso, Noel E. Sam, Emily Bongard, Esther C. Kanduma, Mramba Nyindo, Richard W. Morris, Stephen H. Gillespie*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

144 Citations (Scopus)

Abstract

Patients in whom acid-fast bacilli smear-positive pulmonary tuberculosis was newly diagnosed were randomized to receive 400 mg moxifloxacin, 300 mg isonaizid, or 600 mg rifampin daily for 5 days. Sixteen-hour overnight sputa collections were made for the 2 days before and for 5 days of monotherapy. Bactericidal activity was estimated by the time taken to kill 50% of viable bacilli (vt50) and the fall in sputum viable count during the first 2 days designated as the early bactericidal activity (EBA). The mean vt 50 of moxifloxacin was 0.88 days (95% confidence interval [CI], 0.43-1.33 days) and the mean EBA was 0.53 (95% CI 0.28-0.79). For the isoniazid group, the mean vt50 was 0.46 days (95% CI, 0.31-0.61 days) and the mean EBA was 0.77 (95% CI, 0.54-1.00). For rifampin, the mean vt50 was 0.71 days (95% CI, 0.48-0.95 days) and the mean EBA was 0.28 (95% CI, 0.15-0.41). Using the EBA method, isoniazid was significantly more active than rifampin (p < 0.01) but not moxifloxacin. Using the vt50 method, isoniazid was more active than both rifampin and moxifloxacin (p = 0.03). Moxifloxacin has an activity similar to rifampin in human subjects with pulmonary tuberculosis, suggesting that it should undergo further assessment as part of a short course regimen for the treatment of drug-susceptible tuberculosis.

Original languageEnglish
Pages (from-to)1342-1345
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume168
Issue number11
DOIs
Publication statusPublished - 1 Dec 2003

Keywords

  • Africa
  • Clinical trials
  • Quinolone
  • Tuberculosis

Fingerprint

Dive into the research topics of 'The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis'. Together they form a unique fingerprint.

Cite this